Diagnostics Accelerator and Target ALS Foundation Biomarker Discovery RFP


Event details

Date 06.05.2022  
Category Call for proposal
  • Letter of Intent: Wednesday, March 2, 2022
  • Full Proposals Solicited : Friday, March 11, 2022
  • Deadline for Submission of Full Proposals : Friday, May 6, 2022
  • Funding Decisions Announced : Friday, May 27, 2022

Advancing biomarkers for neurodegeneration.

Alzheimer’s disease, frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) are all heterogeneous at the clinical, neuropathological and genetic levels, and increasing evidence indicates that the three disorders share common features. As such, biomarker research targeting mechanisms or pathways common across the three diseases holds promise to advance and facilitate biomarker discovery and validation.
Two Funding Mechanisms:

Option 1: As a grant through Target ALS Foundation.

Two broad categories:
  • Exploratory pilot studies that aim to test the utility of an existing fluid biomarker approach for the first time in an Alzheimer's disease or related dementia and ALS population. These projects should already have preliminary human data from another neurodegenerative disease indication. Support will also be considered for transferring methods to measure biomarkers of interest currently in CSF to blood, saliva or urine.
  • Proof-of-principle analyses of biomarkers at a small scale (e.g., 50-100 human samples) that are supported by human data demonstrating that the candidate markers correspond with disease pathophysiology in Alzheimer’s disease or FTD and ALS. For peripheral biomarkers, preliminary assay performance data for the proposed studies should be included.
  • Available funding $300,000 USD per year, maximum two-year period
Option 2: As a mission-related investment from the Diagnostics Accelerator at the ADDF

Projects that succeed in the exploratory or proof-of-principle stage funded by Target ALS may be eligible for follow-on funding provided the biomarker is involved in Alzheimer’s disease or related dementia disease pathophysiology. Direct applications are also welcome, providing the appropriate technical and business data packages can be assembled. It is the aim of the Diagnostics Accelerator to advance biomarkers to the clinic.
  • Available funding: Collaborative projects, as well as individual labs that are part of the collaborative projects funded through Target ALS Foundation, may be eligible for follow on funding through a one-time award of up to $500,000 via a mission-related investment from the Diagnostics Accelerator, provided the biomarker is involved in Alzheimer’s disease or related dementia disease pathophysiology. Funding will be provided to enable progress through the regulatory path with the aim of making the biomarker related tools and assays available to the worldwide community.

How to apply for either or both options:

Go to the website for Diagnostics Accelerator and Target ALS Foundation Biomarker Discovery RFP; use the “Log-in or Create Account” button at the bottom of the page.

For further information:

For program-related inquiries:
For application submission inquiries: Contact the Research Office for information or if you decide to submit a proposal.

Practical information

  • General public
  • Free


Event broadcasted in